Rheumatic diseases and portal hypertension

SHEN Li, DUAN Weijia, LYU Tingting, JIA Jidong

PDF(564 KB)
PDF(564 KB)
Journal of Clinical Hepatol ›› 2025, Vol. 41 ›› Issue (05) : 812-816. DOI: 10.12449/JCH250503
Expert Forum

Rheumatic diseases and portal hypertension

Author information +
History +

Abstract

Rheumatic diseases are a group of chronic disorders characterized by abnormalities in the immune system，while portal hypertension occurs due to increased blood flow or heightened resistance in the portal venous system or obstruction of hepatic venous outflow. Both rheumatic diseases and their medications can lead to noncirrhotic portal hypertension. The hypercoagulable state associated with rheumatic diseases can result in thrombosis within the portal and hepatic venous systems，and damage to the intrahepatic portal system and hepatic sinusoidal endothelial system can lead to porto-sinusoidal vascular disease and hepatic sinusoidal obstruction syndrome. Moreover，drugs used for the treatment of rheumatic diseases may cause liver parenchymal injury，which further leads to liver fibrosis and cirrhosis，or they may damage the hepatic vascular endothelium and thus cause noncirrhotic portal hypertension. This article elaborates on the mechanisms and characteristics by which common rheumatic diseases and their therapeutic agents lead to portal hypertension，in order to provide insights and assistance for clinical diagnosis，treatment，and follow-up monitoring.

Key words

Rheumatic Diseases / Portal Hypertension / Diagnosis

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
SHEN Li , DUAN Weijia , LYU Tingting , et al. Rheumatic diseases and portal hypertension. Journal of Clinical Hepatol. 2025, 41(05): 812-816 https://doi.org/10.12449/JCH250503

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
[1]
KHANNA R, SARIN SK. Noncirrhotic portal hypertension: Current and emerging perspectives[J]. Clin Liver Dis, 2019, 23(4): 781-807. DOI: 10.1016/j.cld.2019.07.006.
本文引用 [1]
[2]
HE FL, JIA JD. Research advances in porto-sinusoidal vascular disease[J]. J Clin Hepatol, 2024, 40(1):19-23. DOI: 10.12449/JCH240103.
何福亮, 贾继东. 门脉肝窦血管病的研究进展[J]. 临床肝胆病杂志, 2024, 40(1): 19-23. DOI: 10.12449/JCH240103.
本文引用 [1]
[3]
WANLESS IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2, 500 autopsies and a new classification of benign hepatocellular nodules[J]. Hepatology, 1990, 11(5): 787-797. DOI: 10.1002/hep.1840110512.
本文引用 [2]
[4]
TONUTTI A, PUGLIESE N, CERIBELLI A, et al. The autoimmune landscape of Porto-sinusoidal vascular disorder: What the rheumatologist needs to know[J]. Semin Arthritis Rheum, 2024, 67: 152467. DOI: 10.1016/j.semarthrit.2024.152467.
本文引用 [3]
[5]
CERDA REYES E, GONZÁLEZ-NAVARRO EA, MAGAZ M, et al. Autoimmune biomarkers in Porto-sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology[J]. Liver Int, 2021, 41(9): 2171-2178. DOI: 10.1111/liv.14997.
本文引用 [1]
[6]
MATSUMOTO T, KOBAYASHI S, SHIMIZU H, et al. The liver in collagen diseases: Pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver[J]. Liver, 2000, 20(5): 366-373. DOI: 10.1034/j.1600-0676.2000.020005366.x.
本文引用 [1]
[7]
GORITSAS C, ROUSSOS A, FERTI A, et al. Nodular regenerative hyperplasia in a rheumatoid arthritis patient without Felty’s syndrome[J]. J Clin Gastroenterol, 2002, 35(4): 363-364. DOI: 10.1097/00004836-200210000-00020.
本文引用 [1]
[8]
YANG S, QUAN M, LI Y, et al. Porto-sinusoidal vascular disease as the cause of portal hypertension in Felty’s syndrome: A case report and literature review[J]. Biomed Res Int, 2020, 2020: 2618260. DOI: 10.1155/2020/2618260.
本文引用 [2]
[9]
ROSENSTEIN ED, KRAMER N. Felty’s and Pseudo-Felty’s syndromes[J]. Semin Arthritis Rheum, 1991, 21(3): 129-142. DOI: 10.1016/0049-0172(91)90002-h.
本文引用 [1]
[10]
STOCK H, KADRY Z, SMITH JP. Surgical management of portal hypertension in Felty’s syndrome: A case report and literature review[J]. J Hepatol, 2009, 50(4): 831-835. DOI: 10.1016/j.jhep.2008.10.035.
本文引用 [1]
[11]
NOBLE S, LINZ M, CORREIA E, et al. Porto-sinusoidal vascular disease and portal hypertension[J]. Clin Liver Dis, 2024, 28(3): 455-466. DOI: 10.1016/j.cld.2024.03.004.
本文引用 [1]
[12]
AFZAL W, HAGHI M, HASNI SA, et al. Lupus hepatitis, more than just elevated liver enzymes[J]. Scand J Rheumatol, 2020, 49(6): 427-433. DOI: 10.1080/03009742.2020.1744712.
本文引用 [1]
[13]
SOLELA G, DABA M. Budd-Chiari syndrome as an initial presentation of systemic lupus erythematosus associated with antiphospholipid syndrome: A case report with review of the literature[J]. Open Access Rheumatol, 2023, 15: 139-143. DOI: 10.2147/OARRR.S425535.
本文引用 [1]
[14]
IMABAYASHI K, NAKANO K, IWATA S, et al. A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension[J]. Mod Rheumatol Case Rep, 2021, 5(2): 285-291. DOI: 10.1080/24725625.2021.1904607.
本文引用 [2]
[15]
MATSUMOTO T, YOSHIMINE T, SHIMOUCHI K, et al. The liver in systemic lupus erythematosus: Pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data[J]. Hum Pathol, 1992, 23(10): 1151-1158. DOI: 10.1016/0046-8177(92)90033-y.
本文引用 [1]
[16]
YANG QB, HE YL, PENG CM, et al. Systemic lupus erythematosus complicated by noncirrhotic portal hypertension: A case report and review of literature[J]. World J Clin Cases, 2018, 6(13): 688-693. DOI: 10.12998/wjcc.v6.i13.688.
本文引用 [1]
[17]
BESSONE F, POLES N, ROMA MG. Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis[J]. World J Hepatol, 2014, 6(6): 394-409. DOI: 10.4254/wjh.v6.i6.394.
本文引用 [1]
[18]
SUÁREZ-DÍAZ S, GARCÍA-CALONGE M, MENDOZA-PACAS G, et al. Non-cirrhotic portal hypertension in systemic lupus erythematosus[J]. Cureus, 2023, 15(2): e35494. DOI: 10.7759/cureus.35494.
本文引用 [1]
[19]
YOU HX, ZHAO JL, HUANG C, et al. Early initiation of anticoagulation improves the long-term prognosis in patients with antiphospholipid syndrome associated portal vein thrombosis[J]. Front Med (Lausanne), 2021, 8: 630660. DOI: 10.3389/fmed.2021.630660.
本文引用 [2]
[20]
PENGO V, RUFFATTI A, LEGNANI C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome[J]. J Thromb Haemost, 2010, 8(2): 237-242. DOI: 10.1111/j.1538-7836.2009.03674.x.
本文引用 [1]
[21]
KLEIN R, GOLLER S, BIANCHI L. Nodular regenerative hyperplasia (NRH) of the liver-a manifestation of ‘organ-specific antiphospholipid syndrome’?[J]. Immunobiology, 2003, 207(1): 51-57. DOI: 10.1078/0171-2985-00209.
本文引用 [1]
[22]
MERONI PL, BORGHI MO, RASCHI E, et al. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies[J]. Nat Rev Rheumatol, 2011, 7(6): 330-339. DOI: 10.1038/nrrheum.2011.52.
本文引用 [1]
[23]
GIANNAKOPOULOS B, KRILIS SA. The pathogenesis of the antiphospholipid syndrome[J]. N Engl J Med, 2013, 368(11): 1033-1044. DOI: 10.1056/NEJMra1112830.
本文引用 [1]
[24]
YAMAMOTO A, MATSUDA H, HIRAMATSU K, et al. A case of idiopathic portal hypertension accompanying multiple hepatic nodular regenerative hyperplasia in a patient with systemic sclerosis[J]. Clin J Gastroenterol, 2021, 14(3): 820-826. DOI: 10.1007/s12328-021-01348-z.
本文引用 [1]
[25]
TAKAGI K, NISHIO S, AKIMOTO K, et al. A case of systemic sclerosis complicated by idiopathic portal hypertension: Case report and literature review[J]. Mod Rheumatol, 2006, 16(3): 183-187. DOI: 10.1007/s10165-006-0479-1.
本文引用 [1]
[26]
GRAF L, DOBROTA R, JORDAN S, et al. Nodular regenerative hyperplasia of the liver: A rare vascular complication in systemic sclerosis[J]. J Rheumatol, 2018, 45(1): 103-106. DOI: 10.3899/jrheum.170292.
本文引用 [1]
[27]
SAIGUSA R, TOYAMA T, ICHIMURA Y, et al. A case of systemic sclerosis complicated with portal hypertension[J]. J Clin Rheumatol, 2021, 27(8S): S668-S669. DOI: 10.1097/rhu.0000000000001633.
本文引用 [1]
[28]
NAKAMURA M, KONDO H, MORI T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J]. Hepatology, 2007, 45(1): 118-127. DOI: 10.1002/hep.21472.
本文引用 [1]
[29]
NAKANUMA Y, SATO Y, KIKTAO A. Pathology and pathogenesis of portal venopathy in idiopathic portal hypertension: Hints from systemic sclerosis[J]. Hepatol Res, 2009, 39(10): 1023-1031. DOI: 10.1111/j.1872-034X.2009.00555.x.
本文引用 [1]
[30]
READ AE, WIESNER RH, LABRECQUE DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy[J]. Ann Intern Med, 1986, 104(5): 651-655. DOI: 10.7326/0003-4819-104-5-651.
本文引用 [1]
[31]
EISENHAUER T, HARTMANN H, RUMPF KW, et al. Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt. Report of a case and review of the literature[J]. Digestion, 1984, 30(3): 185-190. DOI: 10.1159/000199104.
本文引用 [1]
[32]
LEMLEY DE, DELACY LM, SEEFF LB, et al. Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis[J]. Ann Rheum Dis, 1989, 48(4): 342-346. DOI: 10.1136/ard.48.4.342.
本文引用 [1]
[33]
PRAPROTNIK S, HOCEVAR A, FERLAN-MAROLT V, et al. Azathioprine induced hepatic veno-occlusive disease in systemic lupus erythematosus[J]. Lupus, 2005, 14(6): 493-494. DOI: 10.1191/0961203305lu2143xx.
本文引用 [1]
[34]
MION F, NAPOLEON B, BERGER F, et al. Azathioprine induced liver disease: Nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis[J]. Gut, 1991, 32(6): 715-717. DOI: 10.1136/gut.32.6.715.
[35]
HOLTMANN M, SCHREINER O, KÖHLER H, et al. Veno-occlusive disease (VOD) in Crohn’s disease (CD) treated with azathioprine[J]. Dig Dis Sci, 2003, 48(8): 1503-1505. DOI: 10.1023/a:1024755521423.
本文引用 [1]
[36]
DELEVE LD, WANG X, KUHLENKAMP JF, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease[J]. Hepatology, 1996, 23(3): 589-599. DOI: 10.1002/hep.510230326.
本文引用 [1]
[37]
BAYOUMY AB, SIMSEK M, SEINEN ML, et al. The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review[J]. Expert Opin Drug Metab Toxicol, 2020, 16(2): 111-123. DOI: 10.1080/17425255.2020.1719996.
本文引用 [1]
[38]
de BOER NKH, van BODEGRAVEN AA, JHARAP B, et al. Drug Insight: Pharmacology and toxicity of thiopurine therapy in patients with IBD[J]. Nat Clin Pract Gastroenterol Hepatol, 2007, 4(12): 686-694. DOI: 10.1038/ncpgasthep1000.
本文引用 [1]
[39]
de BOER NK, MULDER CJ, van BODEGRAVEN AA. Nodular regenerative hyperplasia and thiopurines: the case for level-dependent toxicity[J]. Liver Transpl, 2005, 11(10): 1300-1301. DOI: 10.1002/lt.20554.
本文引用 [1]
[40]
DUBINSKY MC, VASILIAUSKAS EA, SINGH H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients[J]. Gastroenterology, 2003, 125(2): 298-303. DOI: 10.1016/s0016-5085(03)00938-7.
本文引用 [1]
[41]
de BOER NK, ZONDERVAN PE, GILISSEN LP, et al. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients[J]. Dig Liver Dis, 2008, 40(2): 108-113. DOI: 10.1016/j.dld.2007.10.013.
本文引用 [1]
[42]
GILISSEN LP, DERIJKS LJ, DRIESSEN A, et al. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?[J]. Dig Liver Dis, 2007, 39(2): 156-159. DOI: 10.1016/j.dld.2006.10.007.
本文引用 [1]
[43]
BAFNA P, SAHOO RR, HAZARIKA K, et al. Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis[J]. Clin Rheumatol, 2021, 40(9): 3605-3613. DOI: 10.1007/s10067-021-05678-8.
本文引用 [1]
[44]
RUIZ-PONCE M, CUESTA-LÓPEZ L, LÓPEZ-MONTILLA MD, et al. Decoding clinical and molecular pathways of liver dysfunction in Psoriatic Arthritis: Impact of cumulative methotrexate doses[J]. Biomed Pharmacother, 2023, 168: 115779. DOI: 10.1016/j.biopha.2023.115779.
[45]
di MARTINO V. Methotrexate-induced liver fibrosis: The end of a long-held belief[J]. J Hepatol, 2023, 78(5): 896-897. DOI: 10.1016/j.jhep.2023.02.018.
本文引用 [1]
[46]
MORI S, ARIMA N, ITO M, et al. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment[J]. PLoS One, 2018, 13(8): e0203084. DOI: 10.1371/journal.pone.0203084.
本文引用 [1]
[47]
ATALLAH E, GROVE JI, CROOKS C, et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated[J]. J Hepatol, 2023, 78(5): 989-997. DOI: 10.1016/j.jhep.2022.12.034.
本文引用 [1]
[48]
DI MARTINO V, VERHOEVEN DW, VERHOEVEN F, et al. Busting the myth of methotrexate chronic hepatotoxicity[J]. Nat Rev Rheumatol, 2023, 19(2): 96-110. DOI: 10.1038/s41584-022-00883-4.
本文引用 [1]
[49]
ALCORN N, SAUNDERS S, MADHOK R. Benefit-risk assessment of leflunomide: An appraisal of leflunomide in rheumatoid arthritis 10 years after licensing[J]. Drug Saf, 2009, 32(12): 1123-1134. DOI: 10.2165/11316650-000000000-00000.
本文引用 [1]
[50]
LEE SW, PARK HJ, KIM BK, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate[J]. Arthritis Res Ther, 2012, 14(5): R232. DOI: 10.1186/ar4075.
本文引用 [1]
[51]
AVOUAC J, DEGRAVE R, VERGNEAULT H, et al. Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index[J]. Clin Exp Rheumatol, 2022, 40(1): 150-157. DOI: 10.55563/clinexprheumatol/usddjr.
本文引用 [1]
[52]
BILASY SE, ESSAWY SS, MANDOUR MF, et al. Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis[J]. Pharmacol Rep, 2015, 67(1): 102-114. DOI: 10.1016/j.pharep.2014.08.009.
本文引用 [1]
[53]
ELSHAER RE, TAWFIK MK, NOSSEIR N, et al. Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K/mTOR/NFκB pathway[J]. Life Sci, 2019, 235: 116824. DOI: 10.1016/j.lfs.2019.116824.
本文引用 [1]

申梨负责课题设计，资料分析，撰写论文；段维佳、吕婷婷参与收集数据，修改论文；贾继东负责拟定写作思路，指导撰写文章并最后定稿。

Funding

National Natural Science Foundation of China(82100633)

Comments

PDF(564 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Clinical Hepatol, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉